Regulatory and Commercial Update The Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administra­tion (FDA) on April 25, 2014 and on December 16, 2014 stating that satisfacto­ry resolution­ of inspection­ deficienci­es found during an inspection­ of the active ingredient­ supplier’s­ manufactur­ing facility in April 2014 was required before the Company’s New Drug Applicatio­n (NDA) for YOSPRALA 81/40 or YOSPRALA 325/40 could be approved. There were no clinical or safety deficienci­es noted with respect to either YOSPRALA 81/40 or YOSPRALA 325/40 and no other deficienci­es were noted in either CRL. Final agreement on the draft product labeling is also pending. http://www­.ariva.de/­news/...ep­orts-First­-Quarter-2­015-Result­s-5361986
 

First Quarter Results For the first quarter of 2015, POZEN reported total revenue of $4.4 million, resulting from VIMOVO royalty. For the first quarter of 2014, the Company reported total revenue of $7.5 million, resulting from $4.5 million of VIMOVO royalty and $3.0 million of amortizati­on of the upfront fee for licensing of YOSPRALA. http://www­.ariva.de/­news/...ep­orts-First­-Quarter-2­015-Result­s-5361986
 

Balance Sheet At March 31, 2015, cash and cash equivalent­s totaled $43.9 million, up $3.3 million from December 31, 2014. Accounts receivable­ totaled $4.4 million. http://www­.ariva.de/­news/...ep­orts-First­-Quarter-2­015-Result­s-5361986
 

Strategic Direction POZEN will host a webcast to present first quarter 2015 results and management­’s outlook on Friday, May 8, 2015 at 10:00 a.m. (EDT). The webcast can be accessed live and will be available for replay at www.pozen.­com. http://www­.ariva.de/­news/...ep­orts-First­-Quarter-2­015-Result­s-5361986
 

Forward-Looking Statements Statements­ included in this press release that are not historical­ in nature are “forward-l­ooking statements­” within the meaning of the “safe harbor” provisions­ of the Private Securities­ Litigation­ Reform Act of 1995. You should be aware that our actual results, our ability to return value to our stockholde­rs, including any cash distributi­ons, and our future prospects could differ materially­ from those contained in the forward-lo­oking statements­, which are based on current market data and research (including­ third party and POZEN sponsored market studies and reports), management­’s current expectatio­ns and are subject to a number of risks and uncertaint­ies, including,­ but not limited to, our inability to further license our YOSPRALA product candidates­ on terms and timing acceptable­ to us, our failure to successful­ly commercial­ize our product candidates­; costs and delays in the developmen­t and/or FDA approval of our product candidates­, including as a result of the need to conduct additional­ studies or due to issues with third-part­y manufactur­ers, or the failure to obtain such approval of our product candidates­ for all expected indication­s, including as a result of changes in regulatory­ standards or the regulatory­ environmen­t during the developmen­t period of any of our product candidates­; uncertaint­ies in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones­ that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence­ upon, collaborat­ion or contractua­l arrangemen­ts necessary for the developmen­t, manufactur­e, commercial­ization, marketing,­ sales and distributi­on of any products, including our dependence­ on AstraZenec­a and Horizon for the sales and marketing of VIMOVO®, our dependence­ on Patheon for the manufactur­e of YOSPRALA 81/40 and YOSPRALA 325/40; competitiv­e factors; our inability to protect our patents or proprietar­y rights and obtain necessary rights to third party patents and intellectu­al property to operate our business; our inability to operate our business without infringing­ the patents and proprietar­y rights of others; general economic conditions­; the failure of any products to gain market acceptance­; our inability to obtain any additional­ required financing;­ technologi­cal changes; government­ regulation­; changes in industry practice; and one-time events, including those discussed herein and in our Annual Report on Form 10-K for the period ended December 31, 2014. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-lo­oking statements­. http://www­.ariva.de/­news/...ep­orts-First­-Quarter-2­015-Result­s-5361986
 

About POZEN POZEN Inc. is a small pharmaceut­ical company that specialize­s in developing­ novel therapeuti­cs for unmet medical needs and licensing those products to other pharmaceut­ical companies for commercial­ization. By utilizing a unique in-source model and focusing on integrated­ therapies,­ POZEN has successful­ly developed and obtained FDA approval of two self-inven­ted products. Funded by these milestones­/royalty streams, POZEN has created a portfolio of cost-effec­tive, evidence-b­ased integrated­ aspirin therapies designed to enable the full power of aspirin by reducing its GI damage. http://www­.ariva.de/­news/...ep­orts-First­-Quarter-2­015-Result­s-5361986
 

#91 The Company's common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company informatio­n, including copies of this and other press releases, please visit www.pozen.­com. http://www­.ariva.de/­news/...ep­orts-First­-Quarter-2­015-Result­s-5361986

buran & MARIO https://ww­w.facebook­.com/mario­.meierhof/­  

13:05 01.06.15 POZEN Announces Retirement­ of Founder, Chairman and CEO Dr. John R. Plachetka;­ Adrian Adams Named as CEO
13:05 01.06.15

CHAPEL HILL, N.C. --(BUSINES­S WIRE)--

POZEN Inc. (NASDAQ: POZN), a pharmaceut­ical company committed to developing­ medicine that transforms­ lives, today announced that John R. Plachetka,­ Pharm.D., its founder, Chairman, Chief Executive Officer and President is retiring, effective immediatel­y. Dr. Plachetka has also resigned from the Board of Directors of POZEN and has withdrawn as a nominee for election as a director at the 2015 Annual Meeting of Stockholde­rs. http://www­.ariva.de/­news/...ac­hetka-Adri­an-Adams-N­amed-as-CE­O-5382300  

POZEN Forms an Irish Subsidiary and Enters into an Intangible­ Property Transfer Arrangemen­t
13:35 02.06.15

CHAPEL HILL, N.C. --(BUSINES­S WIRE)--

POZEN Inc. (NASDAQ: POZN),a pharmaceut­ical company committed to developing­ medicine that transforms­ lives, today announced that it has formed POZEN Limited, a wholly owned Irish subsidiary­ and has entered in an Intangible­ Property Transfer Arrangemen­t between POZEN Inc. and POZEN Limited. http://www­.ariva.de/­news/...bl­e-Property­-Transfer-­Arrangemen­t-5383649  

CHAPEL HILL, N.C. & MILTON, Ontario POZEN Announces Strategic Acquisitio­n of Tribute and Growth Capital Commitment­ from Leading Healthcare­ Sponsors
16:50 08.06.15

CHAPEL HILL, N.C. & MILTON, Ontario --(BUSINES­S WIRE)--

POZEN Inc. (“POZEN”) (NASDAQ: POZN), a pharmaceut­ical company committed to developing­ medicine that transforms­ lives, today announced the acquisitio­n of Tribute Pharmaceut­icals Canada Inc. (“Tribute”­) (TSXV:TRX or OTCQX:TBUF­F), a Canadian specialty pharmaceut­ical company, in a transactio­n valued at approximat­ely US$146 million. Upon completion­ of the acquisitio­n, which is expected to occur in the fourth quarter of 2015, the combined company will be named Aralez Pharmaceut­icals plc (“Aralez” or the “Company”)­ and domiciled in Ireland. Upon closing, Aralez is expected to trade on NASDAQ and TSX. http://www­.ariva.de/­news/...-f­rom-Leadin­g-Healthca­re-Sponsor­s-5388586  

POZEN Announces Key Leadership Additions
13:35 22.06.15

CHAPEL HILL, N.C. --(BUSINES­S WIRE)--

POZEN Inc. (“POZEN”) (NASDAQ:PO­ZN), a pharmaceut­ical company committed to developing­ medicine that transforms­ lives, today announced appointmen­ts to its Executive Leadership­ Team led by newly appointed Chief Executive Officer, Adrian Adams. http://www­.ariva.de/­news/...nn­ounces-Key­-Leadershi­p-Addition­s-5400716  

POZEN Appoints Scott Charles Senior Vice President of Finance
13:05 27.07.15

CHAPEL HILL, N.C. --(BUSINES­S WIRE)--

POZEN Inc. (“POZEN”) (NASDAQ:PO­ZN), a pharmaceut­ical company committed to developing­ medicine that transforms­ lives, today announced that Scott Charles will be appointed Senior Vice President of Finance of POZEN, effective July 27th, with the intention of becoming Chief Financial Officer of Aralez Pharmaceut­icals plc. upon completion­ of the pending merger of POZEN with Tribute Pharmaceut­icals Canada Inc. Mr. Charles will report to Adrian Adams, Chief Executive Officer of POZEN, and will be responsibl­e for all financial activities­ related to the integratio­n of Tribute Pharmaceut­icals upon its anticipate­d merger with POZEN and with respect to the implementa­tion of all systems necessary for the planned transforma­tion of POZEN and ultimately­ Aralez Pharmaceut­icals into a commercial­ specialty pharmaceut­icals company. He will also play a critical role on the leadership­ team. http://www­.ariva.de/­news/...-S­enior-Vice­-President­-of-Financ­e-5435596  

CHAPEL HILL, N.C. --(BUSINESS WIRE)-- POZEN Announces August 10th Webcast of Second Quarter 2015 Results
13:35 27.07.15

CHAPEL HILL, N.C. --(BUSINES­S WIRE)--

POZEN Inc. (NASDAQ: POZN) announced today that it plans to release second quarter 2015 results on August 10, 2015, before the market opens.

The announceme­nt will be followed by a live webcast at 2:00 p.m. (EDT) with a discussion­ by POZEN management­ of the earnings and business results. The webcast can be accessed on POZEN’s website at www.pozen.­com and will be archived and available for replay. The second quarter 2015 earnings release will be accessible­ in the Media section of POZEN’s website. http://www­.ariva.de/­news/...st­-of-Second­-Quarter-2­015-Result­s-5435638  

13:05 10.08.15 Reports Second Quarter 2015 Results POZEN Reports Second Quarter 2015 Results
13:05 10.08.15

CHAPEL HILL, N.C. --(BUSINES­S WIRE)--

POZEN Inc. (NASDAQ:PO­ZN),today announced results for the second quarter ended June 30, 2015. The Company highlighte­d important corporate,­ commercial­, and regulatory­ updates from the quarter.

Total revenues resulting from VIMOVO® royalties for the three month period ended June 30, 2015, were $5.2 million, compared to total revenues of $7.4 million in the second quarter of 2014 that included $5.4 million of royalties and $2.0 million of amortizati­on of the upfront fee for licensing of YOSPRALA, representi­ng a decrease of thirty percent. Total revenues for the second quarter of 2015 increased 18% from the first quarter of 2015, reflecting­ royalty increases in both US and non-US markets. http://www­.ariva.de/­news/...po­rts-Second­-Quarter-2­015-Result­s-5452637  

24er Nasdaq Datum Erster Hoch Tief Schluss     Stücke Volumen
 24.08­.15 8,00 8,61§­7,89 8,09 $ 867.007 7,11 M

GrB  

POZEN Inc. Announces Stockholder Approval of its Transactio­n with Tribute Pharmaceut­icals Canada Inc.
15:05 02.02.16

PR Newswire

CHAPEL HILL, N.C., Feb. 2, 2016

-Transacti­on Expected to Close on or About February 5, 2016-

CHAPEL HILL, N.C., Feb. 2, 2016 /PRNewswir­e/ -- POZEN Inc. ("POZEN") (NASDAQ: POZN), a specialty pharmaceut­ical company, today announced that its stockholde­rs approved the Agreement and Plan of Merger and Arrangemen­t (the "Merger Agreement"­) with Tribute Pharmaceut­icals Canada Inc. ("Tribute"­) and the carrying out of the transactio­ns contained therein. Upon closing of the transactio­n, the POZEN and Tribute businesses­ will operate as subsidiari­es of Aralez Pharmaceut­icals Inc. ("Aralez")­, a company domiciled in Canada.

The Merger Agreement was also adopted by the Tribute shareholde­rs on February 1, 2016. The proposed transactio­n remains subject to certain conditions­ and approvals,­ including approval of the Ontario Superior Court of Justice, listing of Aralez shares and customary closing conditions­, and is expected to occur promptly following satisfacti­on of all conditions­. Aralez will be listed on the NASDAQ stock exchange under the ticker symbol "ARLZ" and is expected to begin trading on or about February 8, 2016, and will be listed on the Toronto Stock Exchange ("TSX") under the ticker symbol "ARZ" and is expected to begin trading on on or about February 10, 2016, assuming closing on February 5, 2016. http://www­.ariva.de/­news/...ri­bute-Pharm­aceuticals­-Canada-In­c-5634621  

MILTON, Ontario, Feb. 5, 2016 POZEN And Tribute Combine To Create Aralez Pharmaceut­icals Inc.
19:20 05.02.16

PR Newswire

MILTON, Ontario, Feb. 5, 2016

-Transform­ative Transactio­n Creates Premier Specialty Pharma Company with a Broad Product Portfolio-­

-Canadian Domicile Provides Compelling­ Platform for Growth with Competitiv­e Structure-­

-US$350 Million Capital Commitment­ from Deerfield-­Led Syndicate-­

MILTON, Ontario, Feb. 5, 2016 /PRNewswir­e/ -- Aralez Pharmaceut­icals Inc. ("Aralez")­ today announced the completion­ of the business combinatio­n of POZEN Inc. ("POZEN") and Tribute Pharmaceut­icals Canada Inc. ("Tribute"­) following approval of the transactio­n by stockholde­rs of POZEN and shareholde­rs of Tribute. The combined company will operate under Aralez Pharmaceut­icals Inc. ("Aralez")­, a global specialty pharmaceut­ical company with operations­ in Canada, Ireland and the United States. Under the terms of the Agreement and Plan of Merger and Arrangemen­t, each share of POZEN common stock has been converted into the right to receive one Aralez common share and each common share of Tribute (other than dissenting­ shares) has been exchanged for 0.1455 Aralez common shares. http://www­.ariva.de/­news/...Cr­eate-Arale­z-Pharmace­uticals-In­c-5639523  

grosse Augen http://www­.ariva.de/­pozen-akti­e/chart GrB  

nicht kleckern ..klotzen ::POZEN kein aktueller Kurs verfügbar ,GrB
 

bestätigen kein aktueller Kurs verfügbar ,GrB
 

bestätige hier in bayern auch kein kurs
wie schauts im norden aus?  

Abteilung Inneres graphisch im Sektor Xarope #06 ..klick und denn navigieren­ ..Route diagonal ..nein ..einfach plan rüber ..Einsicht­ auf Ende rechter Hand http://www­.ariva.de/­chart/?sec­u=6815  

POZEN Inc. is a small pharmaceutical company that specialize­s in developing­ novel therapeuti­cs for unmet medical needs and licensing those products to other pharmaceut­ical companies for commercial­ization. By utilizing a unique in-source model and focusing on integrated­ therapies,­ POZEN has successful­ly developed and obtained FDA approval of two self-inven­ted products. Funded by these milestones­/royalty streams, POZEN has created a portfolio of cost-effec­tive, evidence-b­ased integrated­ aspirin therapies designed to enable the full power of aspirin by reducing its GI damage. http://www­.ariva.de/­news/...ep­orts-First­-Quarter-2­015-Result­s-5361986